证券代码：688656 证券简称：浩欧博 公告编号：2023-020 江苏浩欧博生物医药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 6 月 6 日(星期二)下午 16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 二、 说明会召开的时间、地点 三、 参加人员 （如有特殊情况，参会人员可能进行调整） 四、 投资者参加方式 （一）投资者可在 2023 年 6 月 6 日下午 16:00-17:00，通过互联网登录上 证路演中心（http://roadshow.sseinfo.com/），在线参与本次业绩说明会，公 司将及时回答投资者的提问。 （二）投资者可于 2023 年 5 月 30 日(星期二)至 6 月 5 日(星期一)16:00 前 ...

2023 年第一季度报告 证券代码：688656 证券简称：浩欧博 江苏浩欧博生物医药股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人 JOHN LI、主管会计工作负责人李翊及会计机构负责人（会计主管人员）韩书艳保证 季度报告中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 项目 本报告期 本报告期比上年同期 增减变动幅度(%) 营业收入 8,077.47 6.16 归属于上市公司股东的净利润 556.18 -58.99 归属于上市公司股东的扣除非经常性损益的 净利润 367.16 -71.74 经营活动产生的现金流量净额 252.63 -37.44 基本每股收益（元/股） 0.09 -59.09 稀释每股收益（元/股） 0.09 -59.0 ...

Financial Performance - The company's operating revenue for 2022 was 320.39 million RMB, a slight increase of 0.84% compared to 2021[20]. - The net profit attributable to shareholders for 2022 was 41.65 million RMB, a decrease of 51.68% year-on-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 36.87 million RMB, down 49.71% from the previous year[20]. - The basic earnings per share for 2022 was 0.66 RMB, a decline of 52.86% compared to 2021[21]. - The company's total revenue for the reporting period was 320.39 million, a slight increase of 0.84% year-on-year[99]. - The net profit attributable to the parent company was 41.65 million, representing a significant decline of 51.68% compared to the previous year[99]. - The gross margin for allergy reagent products decreased by 4.55 percentage points, while the self-immune reagent products saw a revenue growth of 9.75%[104]. - Domestic sales revenue slightly decreased by 0.66%, while costs increased by 20.10%, leading to a 6.09 percentage point drop in gross margin[105]. - International sales revenue surged by 83.31%, with costs rising by 64.61%, resulting in a gross margin increase of 5.81 percentage points[105]. Dividend and Profit Distribution - The proposed cash dividend for 2022 is CNY 3.0 per 10 shares, totaling CNY 18.9175 million, which accounts for 45.42% of the net profit attributable to shareholders[5]. - The company plans to retain undistributed profits for future use, with no other forms of distribution planned[5]. - The company has a cash dividend policy that complies with its articles of association and shareholder resolutions, ensuring clarity and fairness in profit distribution[182]. - The company has no plans for share repurchase as part of its cash dividend distribution[184]. Research and Development - The company has invested in research and development, allocating 10% of its annual revenue to innovate and enhance its diagnostic technologies, particularly in the field of immunoassays[12]. - The total R&D investment for the year was CNY 38.74 million, representing a 21.88% increase from the previous year, and accounting for 12.09% of total revenue[70]. - The company’s R&D investment as a percentage of operating revenue increased to 12.09%, up 2.09 percentage points from the previous year[21]. - The R&D budget has been increased by 30%, focusing on advanced technologies in molecular diagnostics[152]. - The company has developed advanced technologies such as enzyme-linked immunoassay and nanomagnetic chemiluminescence technology, which are now being industrialized[63]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, targeting new regions in Asia and Europe, aiming to increase its market share by 15% in these areas over the next two years[11]. - The company has set a revenue guidance for the next fiscal year, projecting a growth of 20% to 25% based on the expansion of its product lines and market reach[13]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and expand its technological capabilities, with a focus on companies specializing in immunodiagnostic technologies[11]. - The company aims to achieve CE certification for its new products, which will facilitate entry into the European market and enhance its competitive position[11]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[152]. Product Development and Innovation - New product launches include the "Nabok" brand, which utilizes advanced nanomagnetic chemiluminescence technology, offering higher sensitivity and faster results for allergy and autoimmune disease testing[12]. - The company has expanded its allergy product line to cover 69 types of IgE allergens and 80 types of food-specific IgG allergens, leading the domestic market in detectable IgE allergens[30]. - The company has successfully launched quantitative allergen detection products, which have lowered the cost of testing and facilitated market promotion[60]. - The company is focusing on the development of a chemiluminescence method for the detection of MDA5 antibodies, which is currently a hot topic in the field of autoimmune disease diagnosis[73]. - The company is expanding its allergy quantitative detection menu, maintaining a leading position in the domestic market[76]. Risk Management - The company has detailed various operational risks in the report, which can be found in the "Management Discussion and Analysis" section[4]. - The company has a comprehensive risk management strategy outlined in the report[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a commitment to investors[6]. - The company is at risk of inventory write-offs if procurement or production plans are not managed effectively[93]. - The actual controller holds a high voting power of 68.29%, which may lead to potential governance risks affecting minority shareholders[98]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance[7]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent and coordinated operations among its governing bodies[141]. - The company held three shareholder meetings during the reporting period, with all proposed resolutions being approved without any rejections[144]. - The company’s board of directors has a total of 9 members, with independent directors participating actively in meetings[167]. - The company has not reported any changes in shareholding for several directors and key personnel, indicating stability in management[149]. Employee and Management Compensation - Total compensation for key management personnel during the reporting period amounts to 1,430.31 million yuan[149]. - The total number of employees at the parent company and major subsidiaries is 488, with 254 at the parent company and 234 at subsidiaries[176]. - The company has a structured salary policy that includes fixed salaries and performance bonuses, with adjustments based on annual performance evaluations and company growth[177]. - The company has implemented a budget management mechanism to align personnel and salary budgets with strategic planning[177]. - The company has established a performance evaluation and incentive mechanism for senior management, linking compensation to company performance, with a combination of base salary and performance-based pay[195]. Regulatory Compliance - The company faced regulatory scrutiny, receiving a notice of investigation from the China Securities Regulatory Commission on November 28, 2022, for suspected information disclosure violations[163]. - On December 30, 2022, the company received an administrative penalty decision from the Jiangsu Securities Regulatory Bureau related to the aforementioned investigation[164]. - The company’s audit committee emphasized compliance with the Company Law and regulatory rules during its meetings, ensuring diligent and responsible conduct[170]. Environmental and Social Responsibility - The company emphasizes environmental protection and sustainable development, investing in pollution control and enhancing research and development for precise detection products[198]. - The company is committed to enhancing its ESG practices and establishing a corporate social responsibility management system to promote sustainable development in the industry[200].

江苏浩欧博生物医药股份有限公司 证券简称：浩欧博 证券代码：688656 投资者关系活动记录表 （2022 年 05 月） | --- | --- | |--------------|--------------------------------------------------------------| | | | | 投资者关系活 | √特定对象调研 □分析师会议 □媒体采访 | | 动类别 | √业绩说明会 □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称 | 2022 年 05 月 09 日 德邦医药有限公司 | | | 中国东方资产管理股份有限公司 | | | 2022 年 05 月 10 日 宝盈基金管理有限公司 | | | 国联安基金管理有限公司、南方基金管理股份有限公 | | | 司、天弘基金管理有限公司、西南证券股份有限公司、 | | | 新华人寿保险股份有限公司、中金基金管理有限公司、 | | | 中融基金管理有限公司 | | | 2022 年 05 月 11 日 方正医药有限公司、上海中岩投 | | | 资咨询有限公司、光大保德信基金管理有限公司、深圳 ...

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人 JOHN LI、主管会计工作负责人李翊及会计机构负责人（会计主管人员）韩书艳 保证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 2022 年第三季度报告 证券代码：688656 证券简称：浩欧博 江苏浩欧博生物医药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期末比上 年同期增减变动幅度 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | (%) | | | | (%) | | | | 营业收入 | 103,324,052.55 | 16.97 | 254,601,0 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[1]. - The company expects a revenue growth of 20% for the second half of 2022, projecting total revenue to reach RMB 1.44 billion by the end of the year[1]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY in the first half of 2022, representing a 25% growth year-over-year[12]. - The company's operating revenue for the first half of 2022 was RMB 151.28 million, an increase of 2.53% compared to RMB 147.54 million in the same period last year[21]. - The net profit attributable to shareholders decreased by 45.96% to RMB 24.36 million from RMB 45.08 million year-on-year[21]. - The basic earnings per share dropped by 48.22% to RMB 0.3863, while diluted earnings per share fell by 48.61% to RMB 0.3834[22]. - The net cash flow from operating activities was RMB 27.51 million, down 17.26% from RMB 33.25 million in the previous year[21]. User Growth and Market Expansion - User data indicates a growth in the active user base, reaching 500,000 users by June 30, 2022, up from 400,000 at the end of 2021, marking a 25% increase[1]. - Market expansion efforts include entering two new provinces in China, expected to increase market share by 10%[1]. - The company is expanding its market presence by entering new regions, with plans to establish partnerships in Southeast Asia by the end of 2022[12]. - The company has established a strong market presence with over 550 distributors across more than 30 provinces in China, enhancing its sales and service network[78]. Research and Development - The company is investing RMB 100 million in R&D for new diagnostic technologies aimed at expanding its product portfolio[1]. - The total R&D investment for the reporting period was ¥15,460,025.21, representing a 20.40% increase from ¥12,840,265.43 in the same period last year[64]. - Research and development expenses accounted for 10.22% of operating revenue, an increase of 1.52 percentage points from the previous year[22]. - The R&D department is structured to enhance product innovation and quality, focusing on new functional products and technology absorption[38]. - The company has developed core technologies in enzyme-linked immunoassay and chemiluminescence, with several technologies already reaching commercialization[58]. Product Development and Innovation - New product launches in the allergy testing segment are anticipated to contribute an additional RMB 200 million in revenue for the second half of 2022[1]. - New product developments include the launch of the "Nabok" brand, which utilizes advanced nanomagnetic chemiluminescence technology for autoimmune disease detection, promising higher sensitivity and faster results[13]. - The company has expanded its allergy product line to cover 69 types of IgE allergens and 80 types of food-specific IgG allergens, leading the domestic market in the number of detectable IgE allergens[28]. - The company has successfully developed a full-automatic nanomagnetic chemiluminescence self-immune detection product, with a total investment of ¥2,227.50 million and cumulative investment of ¥1,722.03 million[67]. - The company is developing 12 new autoimmune disease detection projects using magnetic microparticle chemiluminescence technology, enhancing its competitive edge in the market[68]. Strategic Partnerships and Acquisitions - The company is exploring potential acquisitions of smaller biotech firms to enhance its technological capabilities and product offerings[1]. - A strategic partnership with a leading medical institution is expected to enhance the company's research capabilities and drive innovation[1]. - The company has initiated a strategic acquisition of a local biotech firm to enhance its R&D capabilities and product offerings, expected to be finalized by Q4 2022[12]. - The company has established strategic partnerships with leading domestic enterprises, such as KingMed and Mindray, to enhance its market position[78]. Market Trends and Challenges - The ongoing COVID-19 pandemic has increased demand for diagnostic testing, contributing to a 40% rise in sales of the company's testing kits[12]. - The total IgE testing market is projected to grow by 15% annually, providing a favorable environment for the company's allergy testing products[12]. - The self-immune diagnostic market in China is still largely dominated by foreign companies, with a market share of about 80% held by companies like Euroimmun[53]. - The company faces risks from potential changes in industry regulatory policies that could adversely affect its operations and market conditions[94]. - The company relies heavily on imported core raw materials, which poses risks related to supply disruptions and price volatility due to geopolitical factors[99]. Environmental and Compliance Measures - The company has established effective pollution control measures, ensuring compliance with relevant standards for wastewater, waste gas, solid waste, and noise[130]. - The company has implemented an environmental monitoring program, with third-party assessments confirming compliance with national standards, despite increasing pollutant emissions due to expanded production[134]. - The company has committed to reducing carbon emissions by optimizing processes and improving material and equipment utilization, aligning with national carbon neutrality goals[136]. - The company has established an emergency response plan for environmental incidents, including defined responsibilities and communication channels[133]. Shareholder Commitments and Governance - The actual controllers hold 68.29% of voting rights, which raises concerns about potential undue influence on company management and decision-making[100]. - The company has committed to ensuring the safety and liquidity of the raised funds while managing them effectively[183]. - The company will disclose any failure to fulfill commitments in a timely manner and apologize to shareholders and public investors[164]. - The company emphasizes the importance of maintaining the legal rights of all shareholders[164]. - The company has established a commitment to avoid any competition with its core business, ensuring no conflicts of interest arise from related parties[153].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 76.09 million, representing a year-on-year increase of 24.75%[5] - The net profit attributable to shareholders was CNY 13.56 million, with a slight increase of 1.69% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses increased by 17.07% year-on-year, amounting to CNY 12.99 million[7] - The basic earnings per share for the period was CNY 0.22, a decrease of 4.35% compared to the previous year[6] - The total operating profit for Q1 2022 was CNY 16,371,087.78, compared to CNY 14,534,958.39 in Q1 2021, indicating an increase of about 12.7%[21] - The net profit for Q1 2022 was CNY 13,562,324.81, a slight increase from CNY 13,336,533.53 in Q1 2021, representing a growth of approximately 1.7%[21] - The total revenue from sales of goods and services received in Q1 2022 was CNY 86,163,503.68, an increase from CNY 70,738,820.18 in Q1 2021, representing a growth of approximately 21.8%[23] Assets and Liabilities - The total assets at the end of the reporting period were CNY 875.01 million, an increase of 1.28% from the end of the previous year[6] - As of March 31, 2022, the company's total current assets amounted to approximately CNY 520.64 million, a decrease from CNY 569.97 million at the end of 2021, representing a decline of about 8.6%[17] - Cash and cash equivalents decreased to CNY 138.93 million from CNY 449.86 million, indicating a significant reduction of approximately 69.0% year-over-year[17] - The company’s trading financial assets increased to CNY 263.71 million from CNY 5.01 million, showing a substantial growth of approximately 5171.5%[17] - Accounts receivable decreased to CNY 31.23 million from CNY 37.48 million, reflecting a decline of about 16.7%[17] - Inventory increased slightly to CNY 70.33 million from CNY 68.20 million, marking a growth of approximately 3.1%[17] - Non-current assets totaled ¥354,369,881.62 as of March 31, 2022, up from ¥293,947,952.55 at the end of 2021, indicating a growth of 20.5%[19] - Current liabilities increased to ¥76,864,482.98 from ¥86,166,555.85, showing a decrease of 10.5%[19] - The company's equity attributable to shareholders reached ¥786,105,802.45, up from ¥770,001,650.91 at the end of 2021, reflecting a growth of 2.1%[19] Cash Flow - The net cash flow from operating activities was CNY 4.04 million, down 45.76% due to increased material purchases and employee compensation[10] - Cash flow from operating activities for Q1 2022 was CNY 4,038,411.21, down from CNY 7,445,872.43 in Q1 2021, reflecting a decrease of approximately 45.5%[24] - The total cash inflow from investment activities in Q1 2022 was CNY 30,194,986.30, while cash outflow was CNY 353,438,688.26, resulting in a net cash flow of -CNY 323,243,701.96[24] - The cash and cash equivalents at the end of Q1 2022 stood at CNY 138,929,515.77, a significant decrease from CNY 506,416,822.95 at the end of Q1 2021[25] - The total operating cash outflow for Q1 2022 was CNY 85,597,750.10, compared to CNY 65,537,101.84 in Q1 2021, indicating an increase of about 30.6%[24] - The company recorded a cash flow from financing activities of CNY 8,463,334.83 in Q1 2022, a decrease from CNY 479,469,346.49 in Q1 2021[24] Research and Development - Research and development expenses totaled CNY 7.21 million, accounting for 9.48% of operating revenue, a decrease of 1.19 percentage points year-on-year[6] - Research and development expenses increased to ¥7,213,239.18, compared to ¥6,508,135.29 in the same period last year, reflecting a growth of 10.8%[20] - Future outlook includes continued investment in R&D for new products and technologies to maintain competitive advantage in the market[15] Strategic Initiatives - The company is focusing on enhancing its brand influence and improving its marketing service network as part of its long-term strategic development[15] - The establishment of new subsidiaries and increased investment in technology are part of the company's strategy to strengthen its product lines in allergy and autoimmune sectors[15] - The company reported a net profit growth slowdown in Q1 2022 due to increased investments in new product development and expansion of production facilities[15] - The company has not disclosed any significant mergers or acquisitions during the reporting period[15] Shareholder Information - The top shareholder, Hai Rui Xiang Tian Biological Technology, holds 3.51 million shares, accounting for 55.66% of total shares[12] - The total number of ordinary shareholders at the end of the reporting period was 3,753[12] Tax and Expenses - The company reported a tax expense of CNY 2,918,406.39 for Q1 2022, significantly higher than CNY 1,262,762.88 in Q1 2021, reflecting an increase of approximately 131.9%[21] - Total operating costs for Q1 2022 were ¥60,549,001.54, up 23.5% from ¥49,022,520.49 in Q1 2021[20] - Gross profit for Q1 2022 was ¥15,538,324.41, representing a gross margin of 20.4%[20] - The company reported a net investment income of ¥171,807.06, a significant decrease from ¥2,567,085.16 in Q1 2021[20]

Financial Performance - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 20% growth compared to the previous year[153]. - The company's operating revenue for 2021 was CNY 31,770.75 million, representing a 43.20% increase compared to 2020[20]. - The net profit attributable to shareholders for 2021 was CNY 8,619.27 million, a growth of 52.24% year-over-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 7,330.54 million, up 71.49% from the previous year[20]. - The basic earnings per share for 2021 was CNY 1.40, reflecting a 16.67% increase compared to 2020[21]. - The company's total assets at the end of 2021 were CNY 86,391.93 million, a 191.46% increase from the end of 2020[20]. - The cash flow from operating activities for 2021 was CNY 10,479.28 million, representing a 79.98% increase compared to 2020[20]. - The company achieved total revenue of 317.71 million RMB, representing a year-on-year growth of 43.20%[103]. - The net profit attributable to the parent company was 86.19 million RMB, reflecting a year-on-year increase of 52.24%[103]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 5.3 RMB per 10 shares, totaling approximately 33.42 million RMB, which represents 38.77% of the net profit attributable to shareholders for the year 2021[5]. - The company will carry forward the remaining undistributed profits to the next fiscal year[5]. - The company has a structured cash dividend policy that aligns with its long-term development strategy and shareholder interests[179]. Research and Development - The company invested 10.00% of its operating revenue in research and development in 2021[21]. - The total R&D investment for the year reached 31.72 million yuan, a 31.72% increase from the previous year, representing 10% of total revenue[74][75]. - The company has increased its R&D personnel from 62 to 81, with total R&D compensation rising from 12 million RMB to approximately 17.3 million RMB, indicating a commitment to enhancing its research capabilities[86]. - The R&D department is structured to focus on innovation and product quality improvement, with a new department dedicated to autoimmune product development[50]. - The company is focusing on expanding its product offerings in the autoimmune disease testing market, with ongoing projects aimed at improving detection capabilities[78]. Market Expansion and Strategy - The company projects a revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[13]. - The company is expanding its market presence in Europe, aiming to increase its market share by 15% over the next two years[15]. - Market expansion plans include entering three new international markets, projected to contribute an additional $100 million in revenue over the next two years[153]. - A strategic acquisition is planned to enhance the company's product portfolio and strengthen its competitive position in the immunodiagnostic market[12]. Product Development and Innovation - New product developments include the launch of the "Nabok" brand, which utilizes advanced nanomagnetic chemiluminescence technology for higher sensitivity and faster results[14]. - The company has launched a total of 80 food-specific IgG antibody test kits, targeting common food allergens[42]. - The company has developed an enzyme-linked immunoassay product for allergen IgE testing that can detect up to 21 allergens simultaneously, significantly improving testing efficiency and accuracy[70]. - The company has successfully developed multiple allergen detection products, leading the domestic market in the number of specific IgE allergens tested[70]. Operational Risks and Governance - The company has identified various operational risks in its annual report, which are detailed in the "Management Discussion and Analysis" section[4]. - The company has not violated decision-making procedures in providing guarantees to external parties[7]. - The company has established a clear decision-making process involving the shareholders' meeting, board of directors, and supervisory board[146]. - The company adheres to corporate governance standards as per the Company Law and relevant regulations, establishing a robust governance structure[146]. Environmental Responsibility - The company emphasizes environmental protection and sustainable development, adhering to local environmental laws and investing in pollution control measures[189]. - The company has established an environmental monitoring plan, commissioning qualified third parties annually to monitor emissions, with results meeting national standards[197]. - Environmental protection expenditure for 2021 amounted to 716,200 RMB, an increase from 699,100 RMB in 2020, 635,600 RMB in 2019, and 508,800 RMB in 2018[198]. - The company has received no administrative penalties related to environmental issues during the reporting period[199]. Employee Development and Management - The company has implemented a performance-based compensation system, linking bonuses to quarterly and annual assessments, with a focus on retaining core talent[177]. - The total number of employees in the parent company and major subsidiaries is 431, with 239 in the parent company and 192 in subsidiaries[175]. - The company completed 1,618 internal training sessions and 162 external training sessions in 2021, enhancing employee capabilities[178]. - The company has established a high-level talent team to support its development plans[144].

Financial Performance - The company's operating revenue for Q3 2021 was ¥88,334,621.36, representing a year-on-year increase of 35.78%[5] - The net profit attributable to shareholders for Q3 2021 was ¥29,675,291.60, reflecting a year-on-year growth of 51.28%[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥29,924,298.25, up 61.38% year-on-year[5] - Total revenue for the first three quarters of 2021 reached ¥235,876,946.48, a significant increase of 64% compared to ¥143,911,515.75 in the same period of 2020[22] - Operating profit for the first three quarters of 2021 was ¥86,395,501.55, up from ¥44,771,866.59 in the previous year, indicating a growth of 93%[23] - Net profit for the first three quarters of 2021 was ¥74,756,574.85, compared to ¥38,691,673.97 in 2020, representing an increase of 93%[23] - The total comprehensive income for the third quarter of 2021 was CNY 74,756,574.85, compared to CNY 38,727,693.91 in the same period of 2020, representing an increase of approximately 93%[24] Assets and Equity - The total assets at the end of the reporting period were ¥840,842,239.76, an increase of 183.68% compared to the end of the previous year[6] - The total equity attributable to shareholders at the end of the reporting period was ¥758,692,152.47, up 267.61% year-on-year[6] - Total assets as of September 30, 2021, amounted to ¥840,842,239.76, a substantial rise from ¥296,410,327.69 at the end of 2020[21] - The company's equity attributable to shareholders increased to ¥758,692,152.47 from ¥206,387,319.77, a growth of 267%[21] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥44,331,460.00, reflecting a year-on-year increase of 54.17%[6] - Cash flow from operating activities for the first nine months of 2021 was CNY 44,331,460.00, compared to CNY 28,755,128.93 in the same period of 2020, indicating a year-over-year increase of 54%[28] - Cash inflow from investment activities for the first nine months of 2021 was CNY 64,252,050.00, significantly higher than CNY 22,310,762.41 in the same period of 2020, marking an increase of 188%[28] - The net cash flow from financing activities for the first nine months of 2021 was CNY 456,587,826.08, compared to a net outflow of CNY 64,676,514.85 in the same period of 2020, showing a turnaround of CNY 521,264,340.93[29] Research and Development - Research and development expenses for Q3 2021 totaled ¥7,991,320.76, accounting for 9.05% of operating revenue, an increase of 0.08 percentage points year-on-year[6] - Research and development investment reached 7.99 million RMB in Q3 2021, a year-on-year increase of 36.95%[16] - Research and development expenses for the first three quarters of 2021 were ¥20,831,586.19, compared to ¥17,279,484.98 in the same period of 2020, an increase of 20%[22] Market Expansion and Operations - The company is actively expanding its domestic and international markets, with a focus on increasing marketing efforts and brand recognition[16] - The company has established new communication mechanisms with overseas agents to mitigate the impact of the COVID-19 pandemic on international marketing efforts[16] - The company experienced significant growth in performance due to the impact of the COVID-19 pandemic in the previous year[9] - The domestic market demand for the company's main products has recovered and grown, particularly in the sales of chemiluminescent products[14] Production and Capacity - The new factory in Hunan has expanded the company's production capacity and optimized product structure, enhancing competitiveness[14] - The company obtained 33 medical device registration certificates during the reporting period, including 26 new certificates for the automated allergy testing platform, Subok[14] Financial Stability - Total liabilities decreased to ¥82,150,087.29 from ¥90,023,007.92, showing a reduction of approximately 9%[20] - The company's cash and cash equivalents reached ¥146,239,656.14, up from ¥58,815,105.12, indicating a growth of 148%[18] - The total cash and cash equivalents at the end of the third quarter of 2021 amounted to CNY 146,239,656.14, up from CNY 42,781,352.91 at the end of the same quarter in 2020[29]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[1]. - The company reported a significant increase in revenue, with a year-on-year growth of 25% in the first half of 2021[13]. - The company expects to achieve a revenue target of 1 billion yuan for the full year 2021, representing a 20% increase from 2020[15]. - The company's operating revenue for the first half of the year reached ¥147,542,325.12, representing an increase of 87.11% compared to the same period last year[22]. - Net profit attributable to shareholders increased by 136.32% to ¥45,081,283.25, while the net profit after deducting non-recurring gains and losses surged by 590.96% to ¥45,160,515.65[22]. - The company achieved total revenue of 147.54 million yuan, an increase of 87.11% year-on-year[64]. - The net profit attributable to the parent company was 45.08 million yuan, up 136.32% year-on-year[64]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2021, representing a 20% year-over-year growth[138]. User Growth and Market Expansion - User data indicates a growth in active users by 15% compared to the previous year, reaching 1.5 million active users[1]. - User data showed that the number of tests conducted increased by 30% compared to the same period last year, indicating a growing demand for the company's diagnostic products[14]. - User data showed a 15% increase in active users, reaching 2 million by the end of the reporting period[110]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[1]. - The company is expanding its market presence in Europe, aiming for a 15% market share by the end of 2022[13]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share within the next two years[110]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[138]. Product Development and Innovation - New product development includes the launch of two innovative diagnostic kits, projected to contribute an additional RMB 30 million in revenue[1]. - New product launches include the "Nabok" series, which utilizes advanced nanomagnetic chemiluminescence technology for autoimmune disease detection, enhancing sensitivity and speed[14]. - The company plans to invest RMB 50 million in technology upgrades to improve operational efficiency[1]. - The company plans to invest 100 million yuan in technology upgrades and facility expansions over the next two years to support growth[15]. - The company is focusing on the development of rapid detection methods that are sensitive and suitable for automation, which will enhance its product offerings in the international market[51]. - The company is developing a fully automated nano magnetic particle chemiluminescence allergy project covering 25 items, with a projected revenue of RMB 2,600.00 million and a development cost of RMB 156.38 million[53]. - The company is working on a new model of the SMART 6500 chemiluminescence analyzer, with a development cost of RMB 104.16 million and an expected revenue of RMB 49.81 million[53]. Research and Development - Research and development efforts are focused on improving the accuracy of allergy testing products, with a projected completion date for new tests by Q4 2021[14]. - The total R&D investment for the period was approximately ¥12.84 million, representing a 12.20% increase compared to the previous period[48]. - The company has filed a total of 110 patent applications, including 88 invention applications, and has been granted 41 patents, of which 19 are invention patents[46]. - The company has increased its R&D personnel to 70, representing 18.87% of the total workforce, with total R&D compensation amounting to RMB 713.37 million[60]. - The company is focusing on continuous R&D investment in the allergy and autoimmune fields to maintain its competitive edge[65]. Strategic Partnerships and Acquisitions - A strategic acquisition of a local biotech firm is in progress, expected to enhance the company's R&D capabilities and product offerings[1]. - Strategic partnerships are being formed with key healthcare providers to enhance distribution channels and increase product accessibility[14]. - The company is exploring potential acquisitions to diversify its product offerings and strengthen its market position[15]. - The company is exploring strategic acquisitions to enhance its product offerings, with a budget of $100 million allocated for potential deals[110]. - There are ongoing discussions regarding potential mergers and acquisitions to enhance product offerings and market reach, with a budget of 500 million RMB allocated for this purpose[138]. Financial Health and Investments - The company plans to address the funding gap through self-raised funds[150]. - The total assets of the company increased by 12% to $1.2 billion, reflecting strong financial health[122]. - The company has maintained a strong financial position with no non-operating fund occupation reported from major shareholders[140]. - The company reported a cash inflow from operating activities of CNY 160,884,010.47, compared to CNY 86,345,325.49 in the first half of 2020, indicating an increase of 86.1%[186]. - The company received CNY 518,890,428.40 from investment absorption, indicating strong investor confidence[189]. Risks and Challenges - The company has identified potential risks related to regulatory changes, which could impact future operations[1]. - The company faces risks related to the limited market space for food-specific IgG testing products due to academic controversies[70]. - There is a risk of revenue decline for food-specific IgG testing products as hospitals and third-party testing institutions reduce or stop procurement[70]. - The reliance on imported core raw materials poses a risk to the company's production and operational stability[72]. - The COVID-19 pandemic has led to significant fluctuations in performance, particularly affecting the willingness of patients to seek non-urgent testing[73]. Corporate Governance and Compliance - The company has implemented a strict quality management system in compliance with ISO13485 standards[66]. - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating a focus on compliance with environmental regulations[92]. - The company has established an emergency response plan for environmental incidents, including training and communication protocols[97]. - The company confirmed that its actual controlling shareholders and related parties have fulfilled their commitments regarding shareholding and management, ensuring no third-party disputes or restrictions on shares[103]. - The company is committed to minimizing related party transactions and ensuring fair market practices[125].